| Management target | Revenue FY27 |
|---|
| Revenue growth | ₹182 Cr revenue; YoY comparison invalid due to Numed acquisition consolidation. |
|---|---|
| Margins | Gross margin improved to 41.8%; EBITDA impacted by elevated air-freight costs. |
| Order book | 7.5-year exclusive OTC supply agreement with Ebos/TerryWhite worth ₹1300 Cr. |
| Demand visibility | Strong Australian order flow; West Asia disruption causing temporary shipping delays. |
| Management confidence | Confident but pivoting strategy due to local regulatory constraints on manufacturing. |
Growth
Consolidated revenue hit ₹182 Cr. Growth is non-comparable YoY due to Numed pharmaceutical's first-time full-quarter consolidation.
Outlook
Revenue guidance for FY27 held at ₹750 Cr with 17% EBITDA margin target.
Risks
Regulatory changes in Hyderabad halted planned unit upgrades; sudden 120-day price revision lags squeeze margins.
Earnings Call Transcript filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹526.45
- Market cap
- ₹2,326 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 112.0×Sector 47.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Bags ₹204 Cr Order
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
- Value
- ₹204.0 Cr
- Execution
- 3 years
Sai Parenterals Annual Report
Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 to the stock exchanges as required under SEBI (LODR) regulations.
Sai Parenterals Annual General Meeting
Sai Parenterals Limited has submitted the notice for its 25th Annual General Meeting, scheduled to be held on 10th September, 2026 via video conference.
Sai Parenterals Merger & Restructuring Worth ₹15 Cr
Sai Parenterals Limited will acquire a 60% stake in Prathyuk Laboratories Private Limited for ₹15 Crore. This strategic move secures an established R&D setup in the pharma sector.
- Value
- ₹15.00 Cr
Sai Parenterals Merger & Restructuring Worth ₹83.83 Cr
Sai Parenterals Limited will acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 Crore in cash.
- Value
- ₹83.83 Cr